Homepage
Author:
Vaxcyte, Inc.
Posted Date:
June 2, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte, Inc.
June 2, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte, Inc.
May 22, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte, Inc.
May 21, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte, Inc.
May 20, 2026
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Vaxcyte, Inc.
February 12, 2026
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Vaxcyte, Inc.
February 10, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Vaxcyte, Inc.
February 7, 2026
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Vaxcyte, Inc.
February 2, 2026
Vaxcyte Announces Pricing of $550 Million Public Offering
Vaxcyte, Inc.
January 29, 2026
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte, Inc.
January 29, 2026
